Anne Whitaker Appointed as Non-Executive Director

Core Viewpoint - Telix Pharmaceuticals Limited has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025, enhancing its board with her extensive healthcare experience [1][4]. Group 1: Appointment Details - Anne Whitaker brings over 30 years of global corporate experience in the pharmaceutical and biotech sectors, having held board positions in various Nasdaq-listed life sciences companies [2]. - She is currently a Non-Executive Director at Icon PLC and Chair at QurAlis Corporation [2]. - Whitaker has previously served as Chair and CEO of Aerami Therapeutics Holdings Inc., and held senior roles at GlaxoSmithKline, Sanofi, and Bausch Health [3]. Group 2: Board's Perspective - Telix Chairman H Kevin McCann AO expressed that Whitaker is an outstanding addition to the board, bringing expertise in commercial risk management, mergers and acquisitions, and Nasdaq governance [4]. - The board anticipates her contributions as Telix continues its global growth [4]. Group 3: Company Overview - Telix Pharmaceuticals is focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals, addressing unmet medical needs in oncology and rare diseases [4]. - The company is headquartered in Melbourne, Australia, with operations in the United States, Brazil, Canada, Europe, and Japan [4].